1. Dodick DW, Silberstein SD. Migraine prevention. Pract Neurol. 2007;7(6):383-393. doi:10.1136/jnnp.2007.134023
  2. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622. doi:10.1152/physrev.00034.2015
  3. Sacco S, Amin FM, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain. 2022;23(1):67. doi:10.1186/s10194-022-01431-x
  4. Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039. doi:10.1111/head.14153
  5. Giri S, Tronvik E, Linde M, Pedersen SA, Hagen K. Randomized controlled studies evaluating topiramate, botulinum toxin type A, and mAbs targeting CGRP in patients with chronic migraine and medication overuse headache: a systematic review and meta-analysis. Cephalalgia Int J Headache. 2023;43(4):3331024231156922. doi:10.1177/03331024231156922
  6. Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):56. doi:10.1186/s10194-023-01594-1
  7. Haghdoost F, Puledda F, Garcia-Azorin D, et al. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia Int J Headache. 2023;43(4):3331024231159366. doi:10.1177/03331024231159366
  8. Messina R, Huessler EM, Puledda F, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia Int J Headache. 2023;43(3):3331024231152169. doi:10.1177/03331024231152169
  9. Puledda F, Younis S, Huessler EM, et al. Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: a systematic review and network meta-analysis of the literature. Cephalalgia Int J Headache. 2023;43(3):3331024231151419. doi:10.1177/03331024231151419
  10. Seng EK, Martin PR, Houle TT. Lifestyle factors and migraine. Lancet Neurol. 2022;21(10):911-921. doi:10.1016/S1474-4422(22)00211-3
  11. Lipton RB, Buse DC, Sandoe CH, et al. Changes in migraine interictal burden following treatment with galcanezumab: results from a phase III randomized, placebo-controlled study. Headache. 2023;63(5):683-691. doi:10.1111/head.14460
  12. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349. doi:10.1212/01.wnl.0000252808.97649.21
  13. AbbVie. Phase 3 multicenter, randomized, double-blind, placebo-controlled study of BOTOX (botulinum toxin type A) for the prevention of migraine in subjects with episodic migraine. clinicaltrials.gov; 2024. Accessed December 31, 2023. https://clinicaltrials.gov/study/NCT05028569
  14. Lipton RB, Stewart WF, Sawyer J, Edmeads JG, et al. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001;41(9):854-861.
  15. Gronseth GS, Cox J, Getchius TSD. Amendments to the 2011 American Academy of Neurology clinical practice guideline process manual. Published online 2016. Accessed October 3, 2023. https://www.aan.com/siteassets/home-page/policy-and-guidelines/guidelines/about-guidelines/15processmanualamendment_v607.pdf
  16. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826. doi:10.1212/WNL.0000000000002560
  17. Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia Int J Headache. 2015;35(6):478-488. doi:10.1177/0333102414547138
  18. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia Int J Headache. 2010;30(7):793-803. doi:10.1177/0333102410364676
  19. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia Int J Headache. 2010;30(7):804-814. doi:10.1177/0333102410364677
  20. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241-254. doi:10.1177/0333102420905132
  21. Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain. 2021;22(1):15. doi:10.1186/s10194-021-01230-w
  22. Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695-706. doi:10.1056/NEJMoa2035908
  23. Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10404):775-785. doi:10.1016/S0140-6736(23)01049-8
  24. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60. doi:10.1016/S0140-6736(20)32544-7
  25. Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia Int J Headache. 2022;42(2):108-118. doi:10.1177/03331024211053571
  26. Pavelic AR, Wöber C, Riederer F, Zebenholzer K. Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells. 2022;12(1):143. doi:10.3390/cells12010143
  27. Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607. doi:10.1016/S1474-4422(22)00185-5
  28. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280-2287. doi:10.1016/S0140-6736(18)32534-0
  29. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030-1040. doi:10.1016/S0140-6736(19)31946-4
  30. Kuruppu DK, Tobin J, Dong Y, et al. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments. BMC Neurol. 2021;21(1):175. doi:10.1186/s12883-021-02196-7
  31. Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C. Hypertension: a new safety risk for patients treated with erenumab. Headache. 2021;61(1):202-208. doi:10.1111/head.14051
  32. Kudrow D, Dafer R, Dodick DW, et al. Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: post hoc analysis of pooled long-term clinical trial data. Headache. 2023;63(3):418-428. doi:10.1111/head.14485
  33. Alsaadi T, Noori S, Varakian R, Youssef S, Almadani A. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE. BMC Neurol. 2022;22(1):221. doi:10.1186/s12883-022-02710-5
  34. Boudreau GP. Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study. Anesth Pain Res. 2020;4(1):1-4.
  35. Schwedt T, Reuter U, Tepper S, et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018;19(1):92. doi:10.1186/s10194-018-0923-6
  36. Detke HC, Millen BA, Zhang Q, et al. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache. 2020;60(2):348-359. doi:10.1111/head.13691
  37. Winner PK, Spierings ELH, Yeung PP, et al. Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache. 2019;59(10):1743-1752. doi:10.1111/head.13654
  38. Goadsby PJ, Dodick DW, Martinez JM, et al. Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry. 2019;90(8):939-944. doi:10.1136/jnnp-2018-320242
  39. McAllister PJ, Turner I, Reuter U, et al. Timing and durability of response to erenumab in patients with episodic migraine. Headache. 2021;61(10):1553-1561. doi:10.1111/head.14233
  40. Iannone LF, Burgalassi A, Vigani G, et al. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study. Cephalalgia Int J Headache. 2023;43(4):3331024231160519. doi:10.1177/03331024231160519
  41. Overeem LH, Peikert A, Hofacker MD, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia Int J Headache. 2022;42(4-5):291-301. doi:10.1177/03331024211048765
  42. Overeem LH, Lange KS, Fitzek MP, et al. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study. Front Neurol. 2023;14:1154420. doi:10.3389/fneur.2023.1154420
  43. Mullin K, Kudrow D, Croop R, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 2020;94(20):e2121-e2125. doi:10.1212/WNL.0000000000008944
  44. Berman G, Croop R, Kudrow D, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60(8):1734-1742. doi:10.1111/head.13930
  45. Adams AM, Lama JCD, Serrano D, et al. Real-world effectiveness of ubrogepant for the acute treatment of migraine when used in combination with an anti–calcitonin gene–related peptide monoclonal antibody preventive: results from the COURAGE study (P10-2.003). Neurology. 2022;98(18 Suppl). Accessed October 3, 2023. https://n.neurology.org/content/98/18_Supplement/3177
  46. Lama JCD, Adams AM, Serrano D, et al. Treatment satisfaction and optimization with real-world use of ubrogepant for the acute treatment of migraine in combination with an anti–calcitonin gene–related peptide monoclonal antibody preventive: results from the COURAGE study (P10-2.001). Neurology. 2022;98(18 Suppl). Accessed October 3, 2023. https://n.neurology.org/content/98/18_Supplement/3129
  47. Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18(1):101. doi:10.1186/s10194-017-0787-1
  48. Graf M, Kim E, Brewer I, et al. Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panel. Headache. 2023;63(4):506-516. doi:10.1111/head.14479
  49. Zhang H, Qi JZ, Zhang ZH, et al. Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):81. doi:10.1186/s10194-023-01625-x
  50. Dodick DW, Goadsby PJ, Schwedt TJ, et al. Ubrogepant for the acute treatment of migraine when administered during the prodrome (premonitory phase): results from a phase 3, randomized, double-blind, placebo-controlled, crossover study (S47.001). Neurology. 2023;100(17 Suppl 2). doi:10.1212/WNL.0000000000202043
Made on
Tilda